Biomedical Engineering Reference
In-Depth Information
30. Cremers B, Flesch M, Sudkamp M, Bohm M (1997) Effects of the novel T-type calcium
channel antagonist mibefradil on human myocardial contractility in comparison with
nifedipine and verapamil. J Cardiovasc Pharmacol 29:692-696
31. Sheng ZH, Rettig J, Cook T, Catterall WA (1996) Calcium-dependent interaction of N-type
calcium channels with the synaptic core complex. Nature 379:451-454
32. Saegusa H, Kurihara T, Zong S, KazunoA MY, Nonaka T, Han W, Toriyama H, Tanabe T
(2001) Suppression of inflammatory and neuropathic pain symptoms in mice lacking the
N-type Ca
2
þ
channel. EMBO J 20:2349-2356
33. Cox B, Denyer J (1998) Patents N-type calcium channel blockers in pain and stroke. Expert
Opin Ther Pat 8:1237-1250
34. Munikumar RD, Hee KJ, Joo HC, Yong SC, Hun YK, Moon HC, Ae NP (2004) 3D QSAR
studies on T-type calcium channel blockers using CoMFA and CoMSIA. Bioorg Med Chem
12:1613-1621
35. Catterall WA, Striessnig J (1992) Receptor sites for Ca
2
þ
channel antagonists. Trends
Pharmacol Sci 13:256-262
36. Opie LH, Frishman WH, Thadani U (1999) Calcium channel antagonists (calcium entry
blockers). In: Opie LH (ed) Drugs for the heart, 4th edn. Saunders WB, Philadelphia
37. Abernethy DR, Schwartz JB (1999) Calcium-antagonist drugs. N Engl
J Med
341:1447-1457
38. Thadani U (1999) Management of stable angina pectoris. Curr Opin Cardiol 14:349-358
39. Glossmann H, Ferry DR, Goll A, Striessnig J, Zernig G (1985) Calcium channels and
calcium channel drugs: recent biochemical and biophysical findings. Arzneimittelforschung
35:1917-1935
40. H
oltje H-D, Marrer S (1987) A molecular graphics study on structure-action relationships of
calcium-antagonistic and agonistic 1,4-dihydropyridines. J Comput Aided Mol Des 1:23-30
41. Matowe WC, Akula M, Knaus EE, Wolowyk MW (1989) AK-2-38, a nifedipine analogue
with potent smooth muscle calcium antagonist action and partial agonist effects on isolated
guinea pig left atrium. Proc West Pharmacol Soc 32:305-307
42. Vo D, Nguyen JT, McEwen CA, Shan R, Knaus EE (2002) Syntheses, calcium
channel agonist-antagonist modulation effects, and nitric oxide release studies of
[3-(benzenesulfonyl)furoxan-4-yloxy]alkyl 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-trifluoro-
methylphenyl, benzofurazan-4-yl, 2-, 3-, or 4-pyridyl)-3-pyridinecarboxylates. Drug Dev
Res 56:1-16
43. Vo D, Matowe WC, Ramesh M, Iqbal N, Wolowyk MW, Howlett SE, Knaus EE (1995)
Syntheses, calcium channel agonist-antagonist modulation activities, and voltage-clamp
studies of isopropyl 1, 4-dihydro-2,6-dimethyl-3-nitro-4-pyridinylpyridine-5-carboxylate
racemates and enantiomers. J Med Chem 38:2851-2859
44. Vo D, Wolowyk MW, Knaus EE (1992) Synthesis and cardioselective beta-adrenergic
antagonist activity of quinolyloxypropanolamines. Drug Des Discov 9:69-78
45. Coburn RA, Wierzba M, Suto MJ, Solo AJ, Triggle AM, Triggle DJ (1988)
1,4-Dihydropyridine antagonist activities at the calcium channel: a quantitative structure-
activity relationship approach. J Med Chem 31:2103-2107
46. Safak C, Simsek R (2006) Fused 1,4-dihydropyridines as potential calcium modulatory
compounds. Mini Rev Med Chem 6:747-755
47. Rose U, Drager M (1992) Synthesis, configuration, and calcium modulatory properties of
enantiomerically pure 5-oxo-1, 4, 5, 6, 7, 8-hexahydroquinoline-3-carboxylates. J Med
Chem 35:2238-2243
48. Miri R, Javidnia K, Sarkarzadeh H, Hemmateenejad B (2006) Synthesis, study of 3D
structures, and pharmacological activities of lipophilic nitroimidazolyl-1,4-dihydropyridines
as calcium channel antagonist. Bioorg Med Chem 14:4842-4849
49. Miri R, Niknahad H, Vazin A, Azarpira A, Shafiee A (2002) Synthesis and smooth muscle
calcium channel antagonist effects of new derivatives of 1,4-dihydropyridine containing
nitroimidzolyl substituent. DARU 10:130-136
€
